Abstract
Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supporting the use of radiolabelled somatostatin receptor analogues (such as dota-peptides) to provide molecular imaging of meningiomas might at least partially overcome these limitations. Moreover, their potential therapeutic usage might enrich the current clinical offering for these patients. Starting from the strengths and weaknesses of structural and functional neuroimaging in meningiomas, in the present article we systematically reviewed the published studies regarding the use of radiolabelled dota-peptides in surgery and radiotherapy planning, in the restaging of treated patients, as well as in peptide-receptor radionuclide therapy of meningioma.
Highlights
Meningioma is the most common primary brain tumour, accounting for 36% of all intracranial tumours [1]
Starting from the strengths and weaknesses of morphological and functional neuroimaging in meningiomas, in the present article we systematically reviewed the published evidence regarding the use of radiolabelled dota-peptides in surgery and radiotherapy planning, in the restaging of treated patients, as well as in peptide-receptor radionuclide therapy
Sommerauer et al [59] studied 23 patients with 64 meningioma who underwent 68Ga-DOTATATE Positron emission tomography” (PET)/CT showing that tracer uptake is significantly correlated with tumour growth rate in World Health Organization (WHO) grades I and II meningioma, whereas no association was observed in WHO grade III lesions
Summary
Meningioma is the most common primary brain tumour, accounting for 36% of all intracranial tumours [1]. 100% at 5 years has been reported after radiation therapy as a first-line treatment in patients not eligible for surgery, regardless of WHO grading [10,11]. This situation is presumably related to the existence of unfavourable biological variables which, in turn, potentially instigate tumour recurrence, regardless of the histopathological grading. Starting from the strengths and weaknesses of morphological and functional neuroimaging in meningiomas, in the present article we systematically reviewed the published evidence regarding the use of radiolabelled dota-peptides in surgery and radiotherapy planning, in the restaging of treated patients, as well as in peptide-receptor radionuclide therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
